← Back
Data updated: Mar 29, 2026
Merck
MRK OncologyInfectious DiseaseCardiovascular
Big Pharma
Research-driven pharma giant anchored by Keytruda, the world's best-selling cancer drug. Strong pipeline in oncology, vaccines (Gardasil), and infectious disease. Known as MSD outside the US.
$64.2B
Revenue (2024)
$240.0B
Market Cap
-
Trials
123
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Competitive Matchups Pro
Loading...
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 55%
5 drugs Phase 3: 149 Phase 2: 80 Phase 1: 116
Infectious Disease 25%
7 drugs Phase 3: 64 Phase 2: 36 Phase 1: 38
Cardiovascular 9%
7 drugs Phase 3: 17 Phase 2: 12 Phase 1: 8
Immunology 7%
2 drugs Phase 3: 13 Phase 2: 13 Phase 1: 18
Metabolic 5%
7 drugs Phase 3: 8 Phase 2: 4 Phase 1: 6
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Immunology
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic, Immunology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
COSETTE other
Cardiovascular, Infectious Disease, Immunology, Oncology
Active (60)
KEYTRUDA QLEX ENFLONSIA WINREVAIR VTAMA XACIATO WELIREG NOXAFIL POWDERMIX KIT VERQUVO RECARBRIO DELSTRIGO PIFELTRO STEGLATRO STEGLUJAN SEGLUROMET PREVYMIS ZINPLAVA BRIDION KEYTRUDA BELSOMRA ASMANEX HFA JANUMET XR DULERA ISENTRESS HD ISENTRESS JANUMET JANUVIA ZOLINZA NEXPLANON CLARINEX-D 12 HOUR FOSAMAX PLUS D ASMANEX TWISTHALER VYTORIN EMEND ZETIA LEVOTHYROXINE SODIUM INVANZ NUVARING PEGINTRON SYLATRON REMERON SOLTAB TEMODAR GANIRELIX ACETATE MAXALT MAXALT-MLT SINGULAIR PROPECIA STROMECTOL REMERON HYZAAR COZAAR PROSCAR LOTRIMIN AF INTRON A DIPROLENE ELSPAR PREGNYL SINEMET SUCCINYLCHOLINE CHLORIDE PROPRANOLOL HYDROCHLORIDE CELESTONE SOLUSPAN
Discontinued (158)
FOLLISTIM AQ FOSAMAX NOXAFIL IMPLANON POTASSIUM CHLORIDE METOCLOPRAMIDE HYDROCHLORIDE METHYLPREDNISOLONE LIPTRUZET PEPCID ZOCOR NASONEX REBETOL PRIMAXIN ZEPATIER PRINIVIL CANCIDAS INTEGRILIN TRUSOPT MANNITOL 25% LOTRISONE DECADRON DIPROLENE AF CLARINEX CLARINEX D 24 HOUR ZEMURON DESOGEN ELOCON VICTRELIS CRIXIVAN NOROXIN VIOXX CHLOR-TRIMETON GUANIDINE HYDROCHLORIDE DUTREBIS COGENTIN ORGATRAX SINEMET CR MEVACOR JUVISYNC AMINOHIPPURATE SODIUM PRINZIDE CLINORIL PAVULON NORCURON ARDUAN RAPLON TIMOLIDE 10-25 BLOCADREN HYPERSTAT VANCERIL DOUBLE STRENGTH
+108 more
Company Info
- First Approval
- 1939-08-17
- Latest
- 2026-02-24
- Applications
- 296
FDA Sponsor Names
SCHERINGMERCKMERCK SHARP DOHMEORGANONSCHERING PLOUGH +10